|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
1963
|
|
gptkbp:ATCCode
|
N06AA01
|
|
gptkbp:brand
|
Norpramin
Pertofrane
|
|
gptkbp:CASNumber
|
50-47-5
|
|
gptkbp:category
|
gptkb:dibenzazepine
antidepressant
norepinephrine reuptake inhibitor
secondary amine tricyclic antidepressant
|
|
gptkbp:contraindication
|
recent myocardial infarction
hypersensitivity to desipramine
|
|
gptkbp:developedBy
|
gptkb:Merck
|
|
gptkbp:eliminationHalfLife
|
12–54 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C18H22N2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
desipramine
|
|
gptkbp:IUPACName
|
5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
weak serotonin reuptake inhibitor
|
|
gptkbp:meltingPoint
|
97–98°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:parent
|
gptkb:imipramine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
80–92%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1547
2889
2995
DB01151
|
|
gptkbp:riskOfOverdose
|
gptkb:arrhythmia
death
coma
seizures
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
weight gain
drowsiness
dry mouth
sexual dysfunction
|
|
gptkbp:synonym
|
desmethylimipramine
|
|
gptkbp:UNII
|
OGG8B83BMV
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:attention_deficit_hyperactivity_disorder
peripheral neuropathy
|
|
gptkbp:bfsParent
|
gptkb:tricyclic_antidepressants
gptkb:imipramine
|
|
gptkbp:bfsLayer
|
6
|